The companies anticipate finalising the acquisition in the third quarter of 2026.
Biotech firm Edgewise Therapeutics said on Monday it would sell its experimental muscular dystrophy drug and related business ...
Under the agreement, Servier will pay $1.55 billion upfront, with up to an additional $1.1 billion tied to regulatory and ...
The French pharma firm Servier is buying an experimental muscular dystrophy drug from Edgewise Therapeutics for $1.55 billion ...
In addition to the upfront fee, Servier has committed up to $1.1 billion in regulatory and commercial milestones to acquire ...
The French drugmaker has agreed to acquire an experimental tablet from Edgewise Therapeutics that some bullish analysts say ...
Edgewise Therapeutics (EWTX) stays a Buy after its $2.65B Servier deal funds EDG-7500 for HCM with key Q2 2026 data. Read ...
Servier has signed the largest licensing deal in its history, paying $1.55 billion upfront for Edgewise Therapeutics' ...
Dyne expects a potential U.S. launch of z-basivarsen in H1 2028, assuming FDA grants Priority Review and approval is received on the anticipated timeline. Dyne also continues to pursue approval ...
The Muscular Dystrophy Family Foundation is offering a $2,000 scholarship for Indiana residents with muscular dystrophy. Apply through June 1, 2026.
For Duchenne and Becker muscular dystrophies, muscle biopsy may show whether dystrophin, a muscle protein, is missing or abnormal, and DNA testing is used to analyze the condition of the related gene.
Tributes poured in for Gilbert Gottfried on Tuesday after news broke that he died in Manhattan. The 67-year-old comedian’s family shared on Twitter that he passed away “after a long illness.” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results